Comparison
5p Partial Monosomy Syndrome C0010314 vs 2 Aminoadipic 2 Oxoadipic Aciduria C1859817
Clinical comparison between 5P Partial Monosomy Syndrome and 2 Aminoadipic 2 Oxoadipic Aciduria for differential diagnosis and treatment planning.
5p Partial Monosomy Syndrome C0010314
Also called Cri-du-chat syndrome, caused by a deletion on chromosome 5. Features include a high-pitched cry, developmental delay, and intellectual disability.
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
A metabolic disorder affecting how the body breaks down certain amino acids. It can cause developmental delays and neurological problems. Treatment includes dietary changes and supportive therapies.
6 comparison axes
Onset
5p Partial Monosomy Syndrome C0010314
0-0
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
0-18
Onset patterns differ
Severity
5p Partial Monosomy Syndrome C0010314
severe
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
moderate
Different severity levels
Chronic
5p Partial Monosomy Syndrome C0010314
Chronic
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
Chronic
Differing course
Communicable
5p Partial Monosomy Syndrome C0010314
No
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
No
Different transmission
Body System
5p Partial Monosomy Syndrome C0010314
congenital
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
metabolic
Same/different system
Category
5p Partial Monosomy Syndrome C0010314
genetic
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
metabolic
Different category
Bottom line
5p-partial-monosomy-syndrome-C0010314 and 2-aminoadipic-2-oxoadipic-aciduria-C1859817 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 5p Partial Monosomy Syndrome C0010314 | 2 Aminoadipic 2 Oxoadipic Aciduria C1859817 | Discriminating power |
|---|---|---|---|
| High-pitched cry | Characteristic cat-like cry is classically described in infancy. | Not an established feature of this metabolic condition. | High |
| Developmental delay | Often present from early infancy with intellectual disability. | May occur, but timing and severity are variable and not fully established. | Moderate |
| Neurologic problems | Congenital neurodevelopmental features are typical. | Neurologic involvement is reported, but a specific pattern is not established. | Low |
When to favor each condition
Choose 5p Partial Monosomy Syndrome C0010314 when
Newborn with distinctive cry and dysmorphic or congenital features
Supports chromosomal evaluation rather than assuming a metabolic diagnosis.
High
Lifelong congenital developmental disability without metabolic decompensation
Fits a chromosomal syndrome better than an amino-acid disorder.
Moderate
Family or clinician suspects Cri-du-chat syndrome
Chromosome 5 deletion testing can confirm or exclude the named syndrome.
High
Choose 2 Aminoadipic 2 Oxoadipic Aciduria C1859817 when
Abnormal amino-acid or organic-acid findings involving aminoadipic metabolites
Points toward a metabolic workup; an abnormal result is not itself a diagnosis.
Moderate
Childhood neurologic or developmental concerns with suspected metabolic disease
Onset may extend beyond the newborn period, unlike typical congenital presentation.
Low
Clinician considers dietary or supportive metabolic management
Management is individualized; no specific regimen is established here.
Low
How key tests differ
| Test | 5p Partial Monosomy Syndrome C0010314 | 2 Aminoadipic 2 Oxoadipic Aciduria C1859817 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May show deletion involving chromosome 5p. | Not expected to identify this metabolic disorder. | A confirmed 5p deletion supports the chromosomal diagnosis. |
| Urine organic acids or plasma amino acids | No characteristic aminoadipic pattern is established. | May show aminoadipic or oxoadipic metabolites, if reported by the laboratory. | Abnormal metabolites need specialist confirmation and are not definitive alone. |
| Genetic or enzyme evaluation | Targets chromosome 5 deletion rather than a metabolic gene. | May be considered when metabolite findings suggest the disorder. | Test choice depends on phenotype and prior results; yield is not established here. |
Prognosis comparison
5p Partial Monosomy Syndrome C0010314
- Outcome
- Usually a lifelong congenital condition with developmental disability; exact outcomes vary.
- Factors
- Deletion extent, associated anomalies, and available developmental support may influence function.
2 Aminoadipic 2 Oxoadipic Aciduria C1859817
- Outcome
- Course is variable and not well established; developmental or neurologic effects may occur.
- Factors
- Age at recognition, neurologic involvement, and response to individualized supportive care.
Time frame: Both are chronic; left is typically evident at birth, while right may present from birth through childhood.
Prognosis cannot be individualized from these labels alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Intellectual disability | Commonly described and often substantial. Possible, but frequency and severity are not established. Severity should be assessed individually. |
| Neurologic impairment | Part of the congenital syndrome. Reported as a possible feature. Specific complications should not be assumed from the label alone. |
| Metabolic decompensation | Not a defining feature. Risk is not clearly established from the supplied description. Urgent metabolic care depends on clinician assessment. |
Patient education highlights
- HighDifferent causes
One condition is a chromosome deletion; the other concerns amino-acid metabolism. Testing, not symptoms alone, distinguishes them.
- HighSupportive care
Developmental, neurologic, and family support are important. Any diet change should be clinician directed.
- MediumResults need context
An abnormal laboratory result is not automatically a diagnosis and should be reviewed by a specialist.